Article
Early circulating tumor DNA dynamics as a pan-tumor biomarker for long-term clinical outcome in patients treated with durvalumab and tremelimumab.
Molecular oncology - 1 Feb 2023
Kansara Maya, Bhardwaj Neeru, Thavaneswaran Subotheni, Xu Chang, Lee Jessica K, Chang Lo-Bin, Madison Russell W, Lin Frank, Hsu Eugene, Patel Vipul Kumar, Aleshin Alexey, Oxnard Geoffrey R, Simes John, Nimeiri Halla, Thomas David M
Abstract excerpt
There is an urgent need to identify biomarkers of early response that can accurately predict the benefit of immune checkpoint inhibitors (ICI). Patients receiving durvalumab/tremelimumab had tumor samples sequenced before treatment (baseline) to identify variants for the design of a personalized circulating tumor (ctDNA) assay. ctDNA was assessed at baseline and at 4 and/or 8 weeks into treatment. Correlations...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.